Press releases
- BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
- Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials
- First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
- BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
- BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
- BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
- BeiGene to Present at Upcoming Investor Conferences
- BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
- BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 79.95 |
---|---|
High | 80.50 |
Low | 78.70 |
Bid | 80.10 |
Offer | 80.15 |
Previous close | 81.05 |
Average volume | 866.22k |
---|---|
Shares outstanding | 1.36bn |
Free float | 1.03bn |
P/E (TTM) | -- |
Market cap | 117.03bn HKD |
EPS (TTM) | -5.12 HKD |
Data delayed at least 15 minutes, as of Apr 18 2024 04:59 BST.
More ▼